Navigation Links
Competitive Technologies Selects RF|Binder as Public Relations Agency of Record
Date:11/5/2009

NEW YORK, Nov. 5 /PRNewswire/ -- RF|Binder Partners today announced that it has been engaged by Competitive Technologies, Inc. (NYSE Amex: CTT) to help roll out and promote it's Calmare Therapy Treatment*, an FDA-approved, non-invasive pain management medical device for treating high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. CTT is working to expand awareness of the brand and electromedical technology among medical professionals, hospitals and the general public. RF|Binder has strong experience among healthcare, pharmaceutical and technology clients.

"We chose RF|Binder because they exhibited a genuine interest and awareness in our space, and a strategic understanding of our business plan and objectives," said John Nano, CTT's Chairman, President and CEO. "Our Calmare Therapy Treatment has full FDA clearance for marketing here in the U.S., is currently in use in Europe and has proven to be an effective alternative to harmful narcotic painkillers, with no adverse side effects. We look forward to working with RF|Binder to increase the exposure of Calmare and to promote the growth and success of the brand."

Calmare has received U.S. FDA 510(k) clearance for U.S. sales and medical device CE certification from the European Union. The innovative technology provides pain control and relief using a unique, non-invasive biophysical process that has been clinically tested and proven with thousands of patients. Unlike drugs, continued treatments can help to steadily diminish the intensity of the pain. The Calmare Therapy Treatment is effective in a high percentage of cases for patients with acute and chronic pain. The product has recently been selected for use at the Paul Carbone Cancer Center at University of Wisconsin-Madison, the University of Miami Pain Management Center and the Massey Cancer Center at Virginia Commonwealth University as well as at La Sapienza University of Rome.

"We're pleased to be working with CTT and its breakthrough technology in pain management," said Robert Ferris, Executive Managing Director at RF|Binder Partners. "Calmare brings CTT to the forefront in meeting the needs of patients in distress and improving palliative healthcare globally."

RF|Binder will be leading an online and traditional media relations campaign to gain exposure for the innovative Calmare Therapy Treatment. For more information about the device, visit www.CalmareTT.com.

About RF|Binder Partners

A member of the Ruder Finn Group, RF|Binder leverages a 60-year heritage of public relations expertise and creative approaches to focus on the changing needs of Fortune 1000 companies, start-ups, non-profit organizations and governments. Headquartered in New York City, RF|Binder Partners operates offices in Boston, Chicago, Los Angeles and Washington, D.C. and maintains affiliate relationships with a global network of full service communications agencies. For more information, please visit www.RFBinder.com.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.

* Calmare Therapy Treatment - Pain Management Therapy Unit Model: MC-5A

    For More Information Contact:

    Robert Ferris
    RF|Binder Partners
    212-994-7505
    Robert.Ferris@RFBinder.com

    Tara Maroney
    RF|Binder Partners
    212-994-7551
    Tara.Maroney@RFBinder.com

SOURCE RF|Binder Partners


'/>"/>
SOURCE RF|Binder Partners
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
2. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
3. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
4. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
5. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
6. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
7. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
8. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
9. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016 Potrero ... system, is pleased to announce the appointment of George ... San Antonio, TX , WellMed is ... servicing over 200,000 patients and HMO members in ... founding WellMed in 1990 out of his own internal medicine ...
(Date:2/11/2016)... Feb. 11, 2016  MiMedx Group, Inc. (NASDAQ: ... amniotic membrane and other birth tissues, human skin and ... and market advanced products and therapies, announced today that ... Global Healthcare Conference in New York ... Michael J. Senken , Chief Financial Officer and ...
(Date:2/11/2016)...  AfterPill.com is reporting that this week,s Centers for ... women who are at risk of unintended pregnancy impacts ... raises the risks of unprotected sex in particular.  ... to the Guttmacher Institute, there are 43 million women ... who have sex without the intention of becoming pregnant.  ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... According to an article published February ... loss dietary supplement, is being recalled due to the discovery that it contains dangerous ... not a single supplement on the market proven to help people safety lose excess ...
(Date:2/11/2016)... , ... February 11, 2016 , ... Registered nurses, licensed ... CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” on Thursday, February ... in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, who will ...
(Date:2/11/2016)... (PRWEB) , ... February 12, 2016 , ... The ... is up from 0.416 in 2013. The SJR uses data taken from the Scopus ... account both the number of citations received by the journal over a three year ...
(Date:2/11/2016)... ... 11, 2016 , ... The Chartis Group, a national advisory ... in the “2015/2016 Best in KLAS: Software and Services” report in two categories: ... and insights firm on a global mission to improve healthcare delivery by amplifying ...
(Date:2/11/2016)... ... February 11, 2016 , ... Thermi™, a world leader ... to announce the promotions of Allison Kelly to executive vice president of the ... vice president of North American capital sales, and Wendy Oseas to vice president ...
Breaking Medicine News(10 mins):